Multi—Disciplinary Treatment for Lung Cancer: Prospects for Increased Cure Rates in the Next Decade

  • L. A. Price
  • Bridget T. Hill
Part of the Ettore Majorana International Science Series book series (EMISS, volume 14)

Abstract

The overall cure rate in lung cancers has not improved·for several decades in spite of the most expert surgery and radiation therapy (1,2). This is because most patients with apparently localised tumours have disseminated micrometastases at presentation. These metastases cannot be detected by current diagnostic techniques. The relationship between our ability to detect tumours in relation to their biological development and the death of the host is illustrated diagramatically in Figure 1.

Keywords

Lung Cancer Small Cell Lung Cancer Tumour Stem Cell Nitrogen Mustard Prophylactic Cranial Irradiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Silverberg, E. 1981. Cancer Statistics, American Cancer Society Professional Education Publications.Google Scholar
  2. 2.
    Cancer Statistics Surviva. 1980. Office of Population Cencuses and Surveys. Series M.B.I. No. 3. London. Her Majesty’s Stationery Office.Google Scholar
  3. 3.
    Goldie, J. H. and Coldman, A. J. (1979). A mathematical model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat. Rep., 63, 1727.Google Scholar
  4. 4.
    Skipper, H. E., Schabel, F. M.Jr., & Wilcox, W. S. 1964. Experimental evaluation of potential anticancer agents. XIII. On the criterial and kinetics associated with the ‘curability’ of experimental leukaemia. Cancer Chemother. Rep., 35, 1.Google Scholar
  5. 5.
    Bruce, W. R., Meeker, B. E. and Valeriote, F. A. 1966. Comparison of the sensitivity of normal haematopoetic and transplanted lymphoma colony-forming cells to chemo-therapeutic agents administered in vivo. J. Natl. Cancer Inst. 37, 233.Google Scholar
  6. 6.
    Cooper, R. G., Holland, J. F. & Glidewell, O. 1979. Adjuvant chermotherapy of breast cancer. Cancer, 44, 793.CrossRefGoogle Scholar
  7. 7.
    Bonadonna, G. and Valagussa, P. 1981. Dose-response effect of adjuvant chemotherapy in breast cancer 1980. New Eng. J. Med., 304, 10.CrossRefGoogle Scholar
  8. 8.
    Price, L. A. and Hill, Bridget T. 1982. Safe and effective 24 hour combination chemotherapy without cis-platin as initial treatment in Head and Neck Cancer: Improved Survival at 5 years. Proceedings of Eighteenth Annual Meeting of the American Society of Clinical Oncology, St. Louis, C786, p 202.Google Scholar
  9. 9.
    Livingston, R. B. and Greenstreet, R. L. 1982. Reinduction prolongs survival in complete responders with small cell lung cancer. Proceedings of the Eighteenth Annual Meeting of the American Society of Clinical Oncology, St. Louis. C588, p.151.Google Scholar
  10. 10.
    Weick, J. K., Joseph, D., Purvis, M. D. & Livingston, R.B. 1982. Divided dose Mitomycin C and Vinblastine in Extensive Non-small Cell Lung Carcinoma. Proceedings Eighteenth Annual Meeting of the American Society of Clinical Oncology, St. Louis. C588, p.151.Google Scholar
  11. 11.
    Price, L. A. 1973. A kinetic approach to the drug treatment of solid tumours. In: The Third Vinca Alkaloids Symposium Ed. Shedden.Google Scholar
  12. 12.
    Price, L. A. & Goldie, J.H. 1971. Twenty-four hour combination chemotherapy for disseminated malignant disease. Brit. Med. J., 4, 336.CrossRefGoogle Scholar
  13. 13.
    Hill, Bridget T. & Price, L.A. 1982. An experimental biological basis for increaseing the therapeutic index of clinical cancer chemotherapy. Annals of the New York Academy of Sciences.Google Scholar
  14. 14.
    Symposium on ‘Safer Cancer Chemotherapy’. Royal College of Surgeons of England. 1981. Eds: Price, L.A., Hill, Bridget T. & Ghilchik, M.W. Publ. Bailliere Tindall.Google Scholar
  15. 15.
    Tate, H.C., Rawlinson, J.B. & Freedman, L.S. 1979. Lancet, 2, 623.CrossRefGoogle Scholar
  16. 16.
    Hill, Bridget T. 1980. Principles of Tumour Growth. In: Scientific Foundations of Respiratory Medicine. Eds: Scadding, J. G. & Cumming, G. p.593.Google Scholar
  17. 17.
    Price, L. A. 1980 Principles of Tumour Growth. In: Scientific Foundations of Respiratory Med icine. Eds. Scadding, J. G. & Cumming, G. p.603.Google Scholar
  18. 18.
    Carter, S. K. & Soper, W. T. 1974. Cancer Treatment Reviews, 1, p.l.Google Scholar
  19. 19.
    Hill, B. T. & Price, L. A. 1977. Concepts and Prospects in Adjuvant Chemotherapy. In: ’Secondary Spread in Breast Cancer’; Vol. 3. New Aspects of Breast Cancer, p. 193. Ed: Stoll Heinemann Medical, London.Google Scholar
  20. 20.
    Price, L. A. & Hill, Bridget, T. 1974. Classification of anti-tumour drugs. Lancet, ii, 172.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • L. A. Price
    • 1
  • Bridget T. Hill
    • 1
  1. 1.LondonUK

Personalised recommendations